FDA Brief

Warning letters Drugs

FDA warning letter to

Lico Industries, LLC., d.b.a. American Towelette Company

High riskIssued Jul 30Posted Aug 11Center for Drug Evaluation and Research (CDER)

FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.

What happened

FDA inspected Lico Industries' drug manufacturing facility in Mohave Valley, Arizona, from February 17 to 19, 2026. Investigators found the quality unit was not doing its job, filling-line tubing held stagnant product residue, and records were unreliable — including backdated quality release labels, temperature data entered when the thermometer did not work, and batches made without batch records. FDA also found microbiological testing of finished non-sterile OTC drug products was limited to aerobic plate counts using a method meant for non-pharmaceutical use.

What FDA found

  1. The quality unit had no written procedures and did not use its authority to oversee manufacturing, review and release of drug products.

    21 CFR 211.22(a) and (d)
  2. The firm did not investigate unexplained discrepancies or batches that failed to meet specifications.

    21 CFR 211.192
  3. Batch production records did not document each significant manufacturing step, and some batches had no records at all.

    21 CFR 211.188(b)
  4. There were no written procedures for handling complaints about drug products.

    21 CFR 211.198(a)
  5. Non-dedicated filling equipment was not cleaned or maintained: stagnant product residue sat inside tubing and in crevices touching the drug product.

    21 CFR 211.67(a)
  6. Microbiological testing of finished products was too limited and used a method not validated for pharmaceutical use.

What FDA wants

FDA tells the company to send a written response within 15 business days covering full assessments and corrective action plans for documentation and data integrity, quality unit authority, investigations, cleaning effectiveness and microbiological testing. FDA strongly recommends hiring a qualified consultant to help with the remediation.

Who should pay attention

  • brands that buy finished OTC towelettes or wipes from this contract manufacturer
  • retailers and distributors selling store-brand OTC wipe products
  • quality teams at other OTC liquid and wipe makers with shared or non-dedicated filling lines

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk